Moderna, Inc. (NASDAQ: MRNA) Q1 2021 earnings call dated May. 06, 2021 Corporate Participants: Lavina Talukdar — Senior Vice President and Head of Investor Relations
Moderna Inc
-(MRNA)
Moderna, Inc. (MRNA) Q1 2021 Earnings Call Transcript
Moderna, Inc. (NASDAQ: MRNA) Q1 2021 earnings call dated May. 06, 2021 Corporate Participants: Lavina Talukdar -- Senior Vice President and Head of Investor
Moderna (MRNA): COVID-19 vaccine helps company deliver first ever profitable quarter
Shares of Moderna Inc. (NASDAQ: MRNA) were down 3% in morning hours on Thursday despite the company reporting the first profitable quarter
Earnings calendar for the week of May 3
Leading stock indexes retreated after gaining mid-week when Wall Street biggies like Apple and Amazon reported impressive quarterly numbers. The Dow Jones
What’s happening on the COVID-19 front? Here are a few updates.
Right about this time last year, the COVID-19 pandemic took over the world with full force as several countries went into complete
Moderna (MRNA) to increase vaccine supply capacity and accelerate pipeline investments
Shares of Moderna Inc. (NASDAQ: MRNA) were up 6% in morning trade on Thursday after the company reported its fourth quarter and
Where do these companies stand in the COVID-19 vaccine race?
After the struggle with the COVID-19 pandemic and its impacts clouding most of 2020, the rollout of vaccines against COVID-19 is the
Moderna (MRNA): Development programs, additional approvals provide optimism
Moderna Inc. (NASDAQ: MRNA) seems to be on a roll right now. The stock has skyrocketed over 500% in the past one
Moderna’s (MRNA) stock gains on COVID-19 vaccine approval from the European Commission
Shares of Moderna Inc. (NASDAQ: MRNA) gained 6.3% in afternoon hours on Wednesday as the company received approval from the European Commission
Is it time to book profits from Moderna?
Moderna (NASDAQ: MRNA) stock has soared a staggering 679% since the beginning of this year. If you did identify the potential of
COVID-19 vaccine: These pharma companies have also made headway
The month of November has been huge for pharmaceutical companies with many submitting positive results from their clinical trials for the development
COVID-19 vaccine: Pfizer (PFE) and Moderna (MRNA) are ahead in the race, where are the others?
Pfizer Inc. (NYSE: PFE) and Moderna Inc. (NASDAQ: MRNA) have made significant progress in their efforts to develop a vaccine against the
Moderna (MRNA) gains as COVID-19 vaccine candidate shows over 94% efficacy
Shares of Moderna Inc. (NASDAQ: MRNA) were up over 8% in morning trade on Monday as the company reported positive results from
Moderna Inc. (MRNA) Q3 2020 Earnings Call Transcript
Moderna Inc. (NASDAQ: MRNA) Q3 2020 earnings call dated Oct. 29, 2020 Corporate Participants: Lavina Talukdar -- Senior Vice President & Head of Investor
Moderna reports higher earnings, wider loss in Q3
Moderna Inc (NASDAQ: MRNA) reported third-quarter 2020 financial results before the opening bell on Thursday. The frontrunner in COVID vaccine research reported
Moderna (MRNA) set to take advantage of opportunity in vaccines
Shares of Moderna Inc. (NASDAQ: MRNA) have gained 246% since the beginning of this year and more than 279% over the past
COVID-19 vaccine development: A look at some of the pharma companies and their progress
The COVID-19 pandemic continues to go on and while the world is slowly coming out of the previously imposed strict lockdown, things
Moderna, Inc. (MRNA) Q2 2020 Earnings Conference Call Transcript
Moderna Inc. (NASDAQ: MRNA) Q2 2020 earnings call dated Aug. 05, 2020 Corporate Participants: Lavina Talukdar -- Head of Investor Relations Stephane Bancel -- Chief Executive
Moderna impresses on the financial side as well in Q2
Moderna, Inc., (Nasdaq: MRNA), a prime contender in Covid-19 vaccine research, on Wednesday, reported second-quarter financial results that smashed past analysts’ estimates.
Moderna Inc (NASDAQ: MRNA) Moderna Vaccine Against COVID-19 Phase 1 Interim Results Publication Call Transcript
Moderna Inc (NASDAQ: MRNA) Moderna Vaccine Against COVID-19 Phase 1 Interim Results Publication Call dated July 15, 2020 Corporate Participants: Lavina Talukdar -- Head
Moderna medical chief: Varying infection rate to be the biggest challenge in Phase 3
A diverse population with varying infection rates will be among the biggest challenges during the phase 3 trials of its COVID-19 vaccine